Index - P/E - EPS (ttm) -1.38 Insider Own 16.27% Shs Outstand 225.41M Perf Week -13.62%
Market Cap 159.78M Forward P/E - EPS next Y -0.70 Insider Trans 0.51% Shs Float 188.87M Perf Month -45.93%
Income -179.82M PEG - EPS next Q -0.19 Inst Own 79.45% Short Float 5.70% Perf Quarter -12.52%
Sales 0.00M P/S - EPS this Y 35.82% Inst Trans 11.74% Short Ratio 8.15 Perf Half Y 39.79%
Book/sh 0.28 P/B 2.54 EPS next Y 6.95% ROA -61.54% Short Interest 10.76M Perf Year -38.94%
Cash/sh 1.31 P/C 0.54 EPS next 5Y 5.20% ROE -480.50% 52W Range 0.45 - 1.88 Perf YTD -22.38%
Dividend Est. - P/FCF - EPS past 5Y 11.99% ROI -69.08% 52W High -62.32% Beta 1.82
Dividend TTM - Quick Ratio 5.94 Sales past 5Y 0.00% Gross Margin - 52W Low 56.53% ATR (14) 0.09
Dividend Ex-Date - Current Ratio 5.94 EPS Y/Y TTM 49.48% Oper. Margin 0.00% RSI (14) 22.04 Volatility 12.38% 9.60%
Employees 135 Debt/Eq 3.38 Sales Y/Y TTM - Profit Margin - Recom 1.80 Target Price 5.72
Option/Short Yes / Yes LT Debt/Eq 3.15 EPS Q/Q 63.89% Payout - Rel Volume 0.60 Prev Close 0.74
Sales Surprise - EPS Surprise -0.82% Sales Q/Q - Earnings Mar 05 BMO Avg Volume 1.32M Price 0.71
SMA20 -28.17% SMA50 -39.49% SMA200 -28.13% Trades
Volume 797,467 Change -3.97%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-05-24 Resumed Wedbush
Outperform
$4
Jul-27-23 Downgrade UBS
Buy → Neutral
$8 → $1.25
Mar-07-23 Downgrade Raymond James
Outperform → Mkt Perform
Mar-01-23 Initiated Guggenheim
Neutral
Dec-07-22 Downgrade SMBC Nikko
Outperform → Neutral
$3
Dec-07-22 Downgrade JP Morgan
Neutral → Underweight
Dec-07-22 Downgrade Barclays
Overweight → Equal Weight
$18 → $2
Oct-20-22 Initiated Goldman
Buy
$22
Sep-21-22 Initiated JP Morgan
Neutral
$17
Sep-19-22 Initiated Wedbush
Outperform
$24
Apr-18-22 Initiated Raymond James
Outperform
$19
Apr-06-22 Initiated UBS
Buy
$19
Jan-10-22 Upgrade SMBC Nikko
Neutral → Outperform
$24
Nov-09-21 Resumed Cantor Fitzgerald
Overweight
$20
Sep-21-21 Resumed Piper Sandler
Overweight
$26
Jun-29-20 Initiated H.C. Wainwright
Buy
$31
Apr-22-20 Initiated Piper Sandler
Overweight
$30
Feb-27-20 Initiated Barclays
Overweight
$21
Dec-03-19 Resumed BofA/Merrill
Buy
Oct-30-19 Initiated Berenberg
Buy
$31
Show Previous Ratings
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM
Loading…
07:40AM
(Associated Press Finance)
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
08:11AM
Loading…
Nov-09-23 08:11AM
07:41AM
(Associated Press Finance)
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
(Associated Press Finance) -5.43%
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
(Zacks Small Cap Research)
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM
Loading…
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
07:31AM
Mar-07-23 03:37PM
Mar-03-23 11:40AM
Feb-01-23 04:25PM
Jan-04-23 12:00PM
09:35AM
Dec-26-22 09:41AM
Dec-06-22 01:19PM
10:00AM
08:19AM
07:15AM
Nov-17-22 02:37PM
Nov-08-22 12:00PM
Nov-03-22 04:01PM
Oct-24-22 08:30AM
Aug-29-22 08:11AM
Aug-09-22 08:01AM
Jul-21-22 06:21PM
Jul-20-22 11:33AM
Jul-19-22 12:00PM
09:46AM
Jul-18-22 09:55AM
Jul-13-22 07:15AM
Jun-09-22 08:30AM
May-26-22 09:55AM
May-23-22 09:55AM
May-10-22 04:01PM
May-06-22 12:20PM
Apr-25-22 07:29AM
Mar-03-22 04:01PM
Feb-28-22 07:01AM
Jan-02-22 08:47AM
Nov-08-21 04:01PM
Nov-02-21 04:01PM
Oct-11-21 08:36AM
Oct-07-21 04:01PM
Oct-03-21 10:45AM
Sep-21-21 08:31AM
Aug-09-21 04:01PM
Aug-02-21 04:01PM
Jul-21-21 05:16AM
Jul-17-21 05:47AM
Jul-07-21 07:01AM
Jun-21-21 04:01PM
Jun-14-21 04:01PM
May-06-21 07:31AM
Apr-20-21 07:50AM
Apr-16-21 07:55AM
Feb-25-21 07:31AM
Feb-19-21 08:01AM
Feb-04-21 07:05AM
Jan-18-21 03:05AM
Dec-19-20 03:54PM
Dec-11-20 05:00PM
Dec-07-20 07:03AM
Nov-16-20 07:01AM
Nov-10-20 04:01PM
02:30PM
08:00AM
Nov-06-20 07:07AM
07:03AM
Oct-13-20 03:02PM
07:04AM
Oct-12-20 08:07AM
Oct-09-20 08:01AM
Sep-30-20 08:38AM
Sep-10-20 07:07AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hasnain Faheem President & CEO Mar 27 '24 Sale 1.16 23,172 26,773 120,293 Mar 28 06:01 PM Giraudo Bryan COO/CFO Mar 27 '24 Sale 1.16 6,430 7,431 92,737 Mar 28 06:05 PM Christian Waage EVP, Tech Ops and Admin Mar 27 '24 Sale 1.16 6,430 7,430 585,934 Mar 28 06:16 PM Peterson Caryn EVP, Regulatory Affairs Mar 18 '24 Sale 1.33 4,018 5,343 49,833 Mar 19 06:50 PM Aranda Richard Chief Medical Officer Mar 18 '24 Sale 1.33 4,018 5,342 198,799 Mar 19 06:50 PM Milligan Sandra Director Nov 15 '23 Buy 0.79 32,000 25,213 32,000 Nov 17 04:01 PM Giraudo Bryan COO/CFO Nov 13 '23 Buy 0.56 200,000 112,880 380,010 Nov 14 06:24 PM Aranda Richard Chief Medical Officer Jun 22 '23 Sale 1.29 1,814 2,340 197,574 Jun 26 04:01 PM
Index RUT P/E - EPS (ttm) -1.48 Insider Own 5.96% Shs Outstand 57.71M Perf Week 0.51%
Market Cap 1.50B Forward P/E - EPS next Y -0.81 Insider Trans -4.80% Shs Float 54.80M Perf Month -7.85%
Income -78.95M PEG - EPS next Q 1.19 Inst Own 95.67% Short Float 6.28% Perf Quarter 4.73%
Sales 60.00M P/S 24.96 EPS this Y 194.96% Inst Trans -9.36% Short Ratio 5.06 Perf Half Y 82.92%
Book/sh 5.83 P/B 4.41 EPS next Y -161.03% ROA -26.05% Short Interest 3.44M Perf Year 8.21%
Cash/sh 5.86 P/C 4.38 EPS next 5Y - ROE -28.59% 52W Range 13.72 - 33.34 Perf YTD 12.08%
Dividend Est. - P/FCF - EPS past 5Y 4.38% ROI -23.45% 52W High -22.92% Beta 2.06
Dividend TTM - Quick Ratio 16.71 Sales past 5Y 2462.45% Gross Margin 94.48% 52W Low 87.32% ATR (14) 1.14
Dividend Ex-Date - Current Ratio 16.71 EPS Y/Y TTM 43.46% Oper. Margin -156.09% RSI (14) 39.11 Volatility 4.59% 3.80%
Employees 112 Debt/Eq 0.00 Sales Y/Y TTM 125.73% Profit Margin -131.59% Recom 1.17 Target Price 43.00
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q 163.72% Payout - Rel Volume 0.48 Prev Close 26.85
Sales Surprise 0.00% EPS Surprise 720.90% Sales Q/Q - Earnings Feb 28 BMO Avg Volume 679.64K Price 25.70
SMA20 -6.16% SMA50 -9.67% SMA200 18.04% Trades
Volume 326,481 Change -4.28%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-30-23 Initiated CapitalOne
Overweight
$32
May-25-23 Resumed Jefferies
Buy
$30 → $40
Aug-25-22 Initiated JMP Securities
Mkt Outperform
$21
Feb-11-22 Initiated BTIG Research
Buy
$55
Oct-12-21 Upgrade JP Morgan
Neutral → Overweight
$49 → $55
Oct-11-21 Upgrade Northland Capital
Market Perform → Outperform
$40
Sep-20-21 Downgrade JP Morgan
Overweight → Neutral
$60 → $49
May-24-21 Initiated Northland Capital
Outperform
$42
May-24-21 Initiated JMP Securities
Mkt Outperform
$48
Jan-06-21 Initiated JP Morgan
Overweight
Dec-16-20 Initiated Piper Sandler
Overweight
$53
Sep-18-20 Reiterated H.C. Wainwright
Buy
$28 → $33
Jul-15-20 Initiated Jefferies
Buy
$27
May-18-20 Reiterated H.C. Wainwright
Buy
$23 → $28
Jul-08-19 Initiated H.C. Wainwright
Buy
$23
May-09-19 Upgrade Stifel
Hold → Buy
$11 → $17
Dec-06-18 Initiated Nomura
Buy
$13
Jan-29-18 Initiated Stifel
Buy
$32
Jul-21-17 Initiated BTIG Research
Buy
$36
Show Previous Ratings
Apr-16-24 09:00AM
Apr-05-24 12:00PM
Apr-03-24 01:52AM
Mar-26-24 07:00AM
Mar-18-24 09:55AM
07:00AM
Loading…
07:00AM
Mar-11-24 07:00AM
Mar-06-24 04:05PM
Mar-01-24 12:20PM
12:00PM
12:00PM
09:55AM
08:50AM
Feb-27-24 04:38PM
(Associated Press Finance)
04:05PM
05:00PM
Loading…
Feb-21-24 05:00PM
Feb-20-24 04:05PM
Feb-15-24 03:13AM
Feb-07-24 05:00PM
Feb-02-24 01:03PM
Feb-01-24 06:35AM
Jan-31-24 04:05PM
Jan-29-24 07:30AM
Jan-12-24 03:02AM
Jan-03-24 07:30AM
Dec-16-23 11:01AM
Dec-13-23 07:30AM
Dec-12-23 09:04AM
Nov-27-23 09:00AM
Nov-16-23 04:05PM
05:50AM
Loading…
05:50AM
Nov-09-23 03:55PM
09:55AM
Nov-04-23 05:42AM
Nov-02-23 06:24PM
(Associated Press Finance)
04:05PM
09:05AM
Nov-01-23 04:05PM
07:30AM
Oct-30-23 04:05PM
Oct-09-23 07:00AM
Oct-03-23 04:05PM
Sep-05-23 07:30AM
Aug-16-23 04:05PM
Aug-09-23 07:00AM
Aug-03-23 04:48PM
(Associated Press Finance)
04:05PM
Jul-18-23 04:05PM
Jul-05-23 09:33AM
Jul-04-23 03:30AM
Jun-30-23 08:50AM
Jun-15-23 09:55AM
Jun-13-23 08:50AM
Jun-09-23 08:05AM
Jun-06-23 07:30AM
Jun-01-23 04:01PM
May-26-23 09:55AM
May-12-23 03:14PM
07:00AM
May-11-23 04:05PM
10:17AM
May-05-23 04:03PM
(Investor's Business Daily) +5.13%
May-04-23 05:02PM
04:05PM
Apr-20-23 09:51PM
Apr-17-23 06:35AM
(Simply Wall St.) +10.03%
Apr-04-23 10:45PM
04:11PM
Mar-21-23 03:49AM
Mar-20-23 06:08AM
Mar-17-23 06:06AM
Mar-15-23 04:01PM
01:39PM
07:30AM
Mar-09-23 11:14AM
Mar-08-23 12:19PM
10:02AM
Mar-07-23 11:54AM
08:00AM
Jan-25-23 03:24AM
Jan-14-23 07:14AM
Dec-21-22 04:05PM
Dec-05-22 09:55AM
Dec-01-22 07:05AM
Nov-16-22 04:05PM
Nov-11-22 09:55AM
05:11AM
Nov-08-22 04:05PM
Nov-03-22 09:16AM
Oct-12-22 06:10AM
Oct-05-22 09:55AM
Oct-02-22 07:39AM
Sep-23-22 12:00PM
Sep-20-22 05:40PM
Aug-10-22 09:55AM
Aug-04-22 07:15PM
04:05PM
Jul-19-22 07:00AM
Jul-18-22 06:11AM
Jul-17-22 09:11AM
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ali Asif Chief Financial Officer Apr 18 '24 Sale 25.11 1,234 30,986 37,163 Apr 19 08:05 PM PATEL DINESH V PH D President and CEO Apr 01 '24 Sale 28.31 25,000 707,750 549,590 Apr 02 08:29 PM SELICK HAROLD E Director Mar 07 '24 Option Exercise 1.89 6,490 12,266 27,996 Mar 11 08:00 PM Ali Asif Chief Financial Officer Mar 01 '24 Option Exercise 12.17 12,000 146,040 52,645 Mar 01 08:45 PM Waddill William D. Director Mar 01 '24 Option Exercise 6.09 12,975 79,018 24,975 Mar 01 08:45 PM PATEL DINESH V PH D President and CEO Mar 01 '24 Sale 31.62 30,000 948,600 574,590 Mar 01 08:46 PM Ali Asif Chief Financial Officer Mar 01 '24 Sale 32.24 14,248 459,318 38,397 Mar 01 08:45 PM Waddill William D. Director Mar 01 '24 Sale 31.34 12,975 406,636 12,000 Mar 01 08:45 PM Ali Asif Chief Financial Officer Feb 29 '24 Sale 30.69 9,939 305,048 40,645 Mar 01 08:45 PM Gupta Suneel Chief Development Officer Jan 09 '24 Option Exercise 7.38 5,000 36,900 192,567 Jan 11 08:00 PM Gupta Suneel Chief Development Officer Jan 09 '24 Sale 25.00 5,000 125,000 187,567 Jan 11 08:00 PM PATEL DINESH V PH D President and CEO Dec 13 '23 Sale 20.08 75,000 1,506,000 534,347 Dec 15 04:30 PM MOLINA ARTURO MD Chief Medical Officer Nov 15 '23 Sale 16.24 1,848 30,012 22,527 Jan 04 08:09 PM Gupta Suneel Chief Development Officer Oct 19 '23 Option Exercise 7.38 20,000 147,600 168,317 Oct 23 04:31 PM PATEL DINESH V PH D President and CEO Oct 18 '23 Option Exercise 4.21 6,000 25,260 609,347 Oct 19 04:55 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
